Stocksigma LogoStocksigma Logo

Evonile Pharma Receives In-Principle BSE Approval for ₹9,000 Million Rights Issue

Evonile Pharma Limited (formerly Novartis India Limited) received in-principle approval from BSE on 30th Oct'26 for its proposed rights issue of partly

Evonile Pharma Receives In-Principle BSE Approval for ₹9,000 Million Rights Issue

Novartis India Ltd · Intimation · 01 Nov 2026, 7:49 pm

Evonile Pharma Receives In-Principle BSE Approval for ₹9,000 Million Rights Issue Evonile Pharma Limited (formerly Novartis India Limited) received in-principle approval from BSE on 30th Oct'26 for its proposed rights issue of partly paid-up equity shares aggregating up to ₹9,000.00 million. The company scheduled meetings of its Board of Directors and Rights Issue Committee on 4th Nov'26 to consider and approve the Letter of Offer and finalize key terms, including the issue price, rights entitlement ratio, and record date.

Original exchange filing (PDF)

More announcements from Novartis India Ltd

All Novartis India Ltd announcements